Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT
1D
and/or the 5-HT
1B
receptor, without agonizing the 5-HT
2B
receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha
2A
and/or the alpha
2B
receptors using the compounds and compositions disclosed herein.
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
申请人:Achillion Pharmaceuticals, Inc.
公开号:US11084800B2
公开(公告)日:2021-08-10
Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
本发明提供了补体因子 D 抑制剂、药物组合物及其用途以及制造工艺。所提供的化合物包括式I、式II、式III、式IV和式V,或其药学上可接受的盐、原药、同位素类似物、N-氧化物或分离异构体,可选药学上可接受的组合物。本文所述的抑制剂以因子 D 为靶点,抑制或调节补体级联。
Nucleophilic trifluoromethylation of anhydrides employing (trifluoromethyl)trimethylsilane: Synthesis of γ-trifluoromethylated γ-butyrolactones
Fluoride-catalyzed nucleophilic trifluoromethylation of acid anhydrides using CF3SiMe3 provided the corresponding gamma-hydroxy-gamma-trifluoromethyl-gamma-butyrolactones. The utility of these adducts was further demonstrated by treatment with Grignard reagents, leading to gamma-trifluoromethylated gamma-butyrolactones. (C) 2013 Elsevier B.V. All rights reserved.